HIGHBuilt-inProduct / Revenue mix
72%
Protein Sciences segment
“10-K Item 1: 'The Protein Sciences segment is the larger of our two segments, representing approximately 72% of our net sales in fiscal 2025.'”
TECH · Concentration risk · 10-K extracted
Bio-Techne (TECH) concentration risks
Updated
The most significant concentration Bio-Techne discloses is Protein Sciences segment at 72%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Bio-Techne’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMBuilt-inGeographic
44%
outside the U.S.
“10-K Item 1A: 'We engage in business globally, with approximately 44% of our sales revenue in fiscal 2025 coming from outside the U.S.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-09-06Bio-Techne's concentration is structural rather than counterparty-driven. The Protein Sciences segment generated approximately 72% of net sales in fiscal 2025, a high-share concentration reflecting the company's core franchise rather than dependence on any single customer, supplier, or region. Geographically, about 44% of fiscal 2025 sales revenue came from outside the U.S., a medium-share exposure that ties a meaningful minority of the business to international demand, currency, and regulatory conditions without being the dominant driver of results. Neither exposure involves a named customer or supplier, so the risk here is business-mix and macro-geographic rather than idiosyncratic: a slowdown in the Protein Sciences franchise specifically, or in international end markets broadly, would move results, but there is no single external counterparty whose failure could disrupt Bio-Techne on its own. On balance, the segment concentration is the more consequential of the two — it defines what the company fundamentally is — while the international revenue share is a secondary, more diversifiable layer. With only two disclosed concentrations, both squarely structural, this is a straightforward risk profile to underwrite.
For the engine’s reasoning on TECH’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| TECH● | Bio-Techne Corp | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.